KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $98.8 million.

  • Biomarin Pharmaceutical's Change in Acquisitions & Divestments fell 3854.66% to $98.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $449.1 million, marking a year-over-year decrease of 2408.51%. This contributed to the annual value of $633.0 million for FY2024, which is 2680.71% down from last year.
  • Biomarin Pharmaceutical's Change in Acquisitions & Divestments amounted to $98.8 million in Q3 2025, which was down 3854.66% from $117.9 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Change in Acquisitions & Divestments peaked at $275.9 million during Q2 2023, and registered a low of $77.8 million during Q1 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's median Change in Acquisitions & Divestments value was $155.8 million (recorded in 2022), while the average stood at $163.3 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Change in Acquisitions & Divestments soared by 10552.79% in 2021 and then plummeted by 4084.83% in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Change in Acquisitions & Divestments stood at $188.9 million in 2021, then fell by 24.45% to $142.8 million in 2022, then decreased by 20.71% to $113.2 million in 2023, then skyrocketed by 36.57% to $154.6 million in 2024, then tumbled by 36.08% to $98.8 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $98.8 million for Q3 2025, versus $117.9 million for Q2 2025 and $77.8 million for Q1 2025.